Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today GALWAY, Ireland, Sept. 15, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a...Read more
SPY072 is a potential first- and best-in-class anti-TL1A antibody for rheumatic diseases targeting quarterly or twice-yearly subcutaneous dosing SKYWAY study is evaluating SPY072 in patients with moderate-to-severely active rheumatoid arthritis (RA), psoriatic arthritis (PsA),...Read more
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid...Read more
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA)...Read more
First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Second Breakthrough Therapy Designation since the start of the Daiichi Sankyo and Merck collaboration Fifteenth Breakthrough Therapy...Read more
CHICAGO / Sep 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac...Read more
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Regeneron Pharmaceuticals | 12.40 2.21 | $572.40 |
| Krystal Biotech | 12.30 8.56 | $155.98 |
| Palatin Technologies | 8.23 4,331.58 | $8.42 |
| Biodesix | 6.97 1,858.96 | $7.35 |
| IDEXX Laboratories | 6.27 0.98 | $647.41 |
| Illumina | 4.99 5.25 | $100.11 |
| Monopar Therapeutics | 4.97 10.10 | $54.19 |
| Mettler-Toledo | 4.88 0.39 | $1,264.42 |
| Bolt Biotherapeutics | 4.76 850.00 | $5.32 |
| NanoVibronix | 4.23 65.18 | $10.72 |
| Medpace | 4.23 0.86 | $495.01 |
| West Pharmaceutical | 3.88 1.53 | $257.38 |
| Clearside Biomedical | 3.69 1,155.09 | $4.01 |
| Waters | 3.15 1.07 | $298.44 |
| Harrow | 2.96 7.51 | $42.38 |
| SIGA Technologies | 2.91 47.09 | $9.09 |
| Natera | 2.81 1.67 | $171.32 |
| Agilent Technologies | 2.45 1.99 | $125.69 |
| Company | Volume | Last Trade |
|---|---|---|
| bioAffinity Technologies | 211,182,985 | $0.36 |
| aTyr Pharma | 161,902,143 | $1.03 |
| Check-Cap | 119,887,876 | $2.38 |
| Adaptimmune Therapeutics | 75,274,994 | $0.07 |
| NanoVibronix | 61,847,983 | $10.72 |
| Pfizer | 42,321,075 | $23.96 |
| Monte Rosa Therapeutics | 37,095,196 | $7.05 |
| ImmunityBio | 24,816,822 | $2.66 |
| Incannex Healthcare | 22,018,216 | $0.53 |
| AVITA Medical | 21,647,712 | $6.65 |
| Recursion | 20,554,853 | $4.74 |
| Intensity Therapeutics | 19,865,512 | $0.23 |
| Cognition Therapeutics | 13,228,923 | $1.55 |
| Microbot Medical | 11,859,772 | $3.46 |
| Novo Nordisk | 11,633,901 | $55.73 |
| Ocugen | 11,576,653 | $1.20 |
| UnitedHealth | 9,734,060 | $349.10 |
| Oscar Health | 9,717,213 | $18.91 |
| Moderna | 9,357,304 | $23.75 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
